Abstract #57192 Published in IGR 16-2

Effect of Early Treatment with Aqueous Suppressants on Ahmed Glaucoma Valve Implantation Outcomes

Pakravan M; Rad SS; Yazdani S; Ghahari E; Yaseri M
Ophthalmology 2014; 121: 1693-1698

See also comment(s) by Steven Gedde

OBJECTIVE: To evaluate the effect of early aqueous suppressant treatment on Ahmed glaucoma valve (AGV) surgery outcomes. DESIGN: Randomized clinical trial. PARTICIPANTS: Ninety-four eyes of 94 patients with refractory glaucoma. METHODS: After AGV implantation, 47 cases (group 1) received topical timolol-dorzolamide fixed-combination drops twice daily when intraocular pressure (IOP) exceeded 10 mmHg, whereas 47 controls (group 2) received conventional stepwise treatment when IOP exceeded target pressure. MAIN OUTCOME MEASURES: Main outcome measures included IOP and success rate (6 mmHg < IOP < 15 mmHg and IOP reduction of at least 30% from baseline). Other outcome measures included best-corrected visual acuity, complications, and hypertensive phase frequency. RESULTS: Groups 1 and 2 were both followed up for a mean of 45±11.6 and 47.2±7.4 weeks, respectively (P = 0.74). Mixed model analysis revealed a significantly greater IOP reduction in group 1 at all intervals (P<0.001). At 1 year, the cases exhibited a significantly higher success rate (63.2% vs. 33.3%; P = 0.008) and reduced hypertensive phase frequency (23.4% vs. 66.0%; P<0.001). CONCLUSIONS: Early aqueous suppressant treatment may improve AGV implantation outcomes in terms of IOP reduction, success rate, and hypertensive phase frequency.

Full article


12.8.2 With tube implant or other drainage devices (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)

Issue 16-2

Select Issue